Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells
Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control
Our Support
KiraGen Bio is proud to join the 2048 Ventures Biotech Studio, marking a pivotal step in our quest to innovate CAR-T therapies for solid tumors. This recognition fuels our journey with vital resources and expert networks, accelerating our path to transforming cancer treatment.
Our collaboration with BioLM propels the development of our state-of-the-art KiraLOGIC® Machine Learning model with the latest in AI technology. This partnership will accelerate the rational design of our TME-Guarded CAR-T cell therapies, showcasing our commitment to pioneering innovative cancer treatment solutions.
Recognitions
HUCP Innovation Fund x CBE Ventures Competition
Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition
Nucleate Activator Program
Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston
Presidents Innovation Challenge
Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge
Finalists in the 2024 M2D2 $200k Grand Challenge
Co-founder and CEO, Aaron Edwards selected to be a Termeer Fellow, a values-driven leadership program for first time biotech founder/CEOs
Co-founder and CSO, Ryan Murray selected to be in 5050 Program, helping foster deep tech scientists/engineers become great founders.
Redefining CAR-T with a differentiated approach:
AI-driven design and multiplex gene editing for superior efficacy against solid tumors.
Our Science
AI-Driven Design
Leveraging machine learning to pinpoint optimal gene editing combinations, enhancing CAR-T cell efficacy against solid tumors.
Multiplex Gene Editing
Employing cutting-edge technology to simultaneously edit 8+ genes, setting a new standard in cell therapy engineering.
Allogeneic CAR-T
Our allogeneic CAR-T cells are engineered to maintain efficacy against immunosuppressive solid tumor microenvironment.